Ted Page
YOU?
Author Swipe
View article: 614. Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered as the Oral Prodrug in Combination with Ceftibuten
614. Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered as the Oral Prodrug in Combination with Ceftibuten Open
Background Xeruborbactam (XERU) is a member of a new class of cyclic boronic acid β-lactamase inhibitors with inhibitory activity against major members of Class A, B, C, and D beta-lactamases. XERU is highly orally bioavailable when admini…
View article: 616. Pharmacodynamics (PD) of the lipopeptide QPX9003 Against <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Mouse Thigh Infection Model
616. Pharmacodynamics (PD) of the lipopeptide QPX9003 Against <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Mouse Thigh Infection Model Open
Background Acinetobacter baumannii and Pseudomonas aeruginosa are important pathogens in hospital-acquired infections and can be resistant to multiple classes of antibiotics. QPX9003 is a novel synthetic lipopeptide that is highly active i…
View article: 615. Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered in Combination with Meropenem
615. Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered in Combination with Meropenem Open
Background Xeruborbactam (XERU) is a member of a new class of cyclic boronic acid β-lactamase inhibitors with inhibitory activity against major members of Class A, B, C, and D beta-lactamases. The purpose of these studies was to determine …